Sakar Healthcare delivered exceptional growth as its oncology segment scales, with EBITDA doubling and margins expanding significantly due to product-mix shifts. Management is pivoting from a non-oncology focus to high-margin oncology formulations and APIs.
IndiaMART InterMESH reported Q2 FY27 consolidated revenue of ₹429 Crore, up 10% YoY, with net profit of ₹91 Crore. EBITDA margin stood at 37% on a consolidated basis.
Atishay Ltd intimates that its Board meeting is scheduled on 3 Nov 2026 to consider unaudited standalone results for Q2 FY27. No financial figures or material decisions are disclosed in this advance notice.
Triveni Engineering & Industries will hold its Board meeting on 2 November 2026 to approve Q2 and H1 FY27 unaudited results. The trading window stays closed until 48 hours after the outcome is filed.
Amrutanjan Health Care scheduled its board meeting for 3 Nov 2026 to consider Q2/H1 results and 1st interim dividend. No financial figures or dividend amount are stated in this advance intimation.
Unisem Agritech Ltd will hold a board meeting on 02 Nov 2026 to consider unaudited standalone half-yearly results for the period ended September 2026. The agenda also covers routine audit, related-party and remuneration items.
Dr. Ritu Garg resigned as Non-Executive Non-Independent Director of Fortis Malar Hospitals on October 27, 2026. The board appointed Dr. S Narayani in her place, effective the same date.
Shraddha Prime Projects Ltd has scheduled its board meeting for 5 November 2026 to consider Q2 FY27 results. This is a prior intimation under Regulation 29(1).
Maruti Suzuki reported record Q2 FY27 net sales of ₹5,06,155 million and net profit of ₹24,149 million. Board approved the Osamu Suzuki Centre of Excellence.
Wipro allotted 2,25,996 equity shares under its ADS RSU, RSU and ESOP/PSU/RSU schemes on 27 Oct 2026. The allotment follows routine exercise of employee stock options and RSUs.
Ushanti Colour Chem filed a non-applicability certificate stating Corporate Governance provisions under SEBI LODR do not apply due to its exclusive NSE SME listing. No monetary or business event is reported.
Rubicon Research scheduled its Board for November 5, 2026, to consider unaudited financial results for the half year ended September 2026. Trading window closed since October 1.
Indoco's CRO AnaCipher received ANVISA Brazil approval for clinical and bioanalytical facilities. This expands its regulatory footprint to conduct bioequivalence studies in Brazil and Latin America.
Upsurge scheduled a board meeting for November 5, 2026 to consider Q1 results and a potential equity fund raise. No specific instrument or amount is specified.
Veegaland Developers has scheduled its Board Meeting for 05 November 2026 to consider unaudited financial results for Q1 and H1 FY27. The filing is a prior intimation; no decisions have been taken yet.
Veefin reported H1 FY27 revenue of ₹238.82 Cr (up 116% YoY) and PAT of ₹24.85 Cr. The company highlighted a ₹920 Cr opportunity pipeline in banking technology.
Premier Limited (in CIRP) intimated that its 21st CoC meeting was rescheduled from December 11 to December 12, 2025. The Resolution Professional filed this under SEBI Regulation 30 for exchange record.
Bajaj Auto's board approved appointing Ms. Pallavi Joshi Bakhru as Non-Executive Independent Director effective January 2027. The appointment is subject to shareholder approval.
India Shelter Finance allotted 39,090 equity shares upon exercise of vested ESOPs under its 2021 and 2023 schemes. Listing formalities for allotted shares are in progress.
Skipper Ltd is seeking shareholder approval via postal ballot to appoint Mr. Rabindra Nath Nayak as Independent Director. E-voting runs from 29 October to 27 November 2026.
CMI Limited, a Corporate Debtor under CIRP, intimated its 49th Committee of Creditors meeting scheduled for 27 October 2026. No resolution details are disclosed.